ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Biological Products

Also written as “Biological”, “AAV2-GDNF gene therapy” and “Biological/Vaccine: BNT162b2 10mcg”.

Its studies are mostly in Parkinson Disease · COVID-19 · Diabetes Mellitus, Type 1 · Carcinoma, Renal Cell · Metabolic Diseases, led by 11 companies.

Drug pageBiological Products: every studyMany companies study it; this page follows only the 12 they lead. All 27 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Dec 6, 201712 company-led studies, 5 open or runningNext primary completion: Aug 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Immune Cellits history only22 open or runningphase 1since Dec 6, 2017Dec 6, 2017none ahead
Anchiano Therapeutics Israelits history only10 open or runningphase 2since Aug 8, 2011Aug 8, 2011none ahead
Bayer11 open or runningphase 2since Feb 14, 2024Feb 14, 2024Aug 31, 2028phase 2 · NCT06285643
BioNTechits history only10 open or runningphase 3since Mar 19, 2021Mar 19, 2021none ahead
diavacs-incits history only10 open or runningphase 2since Sep 18, 2013Sep 18, 2013none ahead
GAIA BioMedicineits history only10 open or runningphase 2since Nov 19, 2021Nov 19, 2021none ahead
Lisata Therapeuticsits history only10 open or runningphase 1since Apr 10, 2001Apr 10, 2001none ahead
Longeveronits history only10 open or runningphase 2since Oct 23, 2015Oct 23, 2015none ahead
Sanofiits history only11 open or runningphase 1since Nov 24, 2025Nov 24, 2025none ahead
Sinopharmits history only10 open or runningphase 2since Jun 11, 2020Jun 11, 2020none ahead

Also a collaborator on its studies: Pfizer, Chengdu Institute of Biological Products and Simoon Record Pharma Information Consulting.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bayer only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 14, 2024First study: phase 2 study in Parkinson DiseaseFirst studyNCT06285643 · 59 enrolled · United States, Germany, Poland and more

Ahead

  1. Aug 31, 2028Primary completion: phase 2 study in Parkinson DiseaseNCT06285643

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Bayer leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06285643Parkinson Disease · United States, Germany, Poland and more2Active, not recruitingAug 31, 202859

How it is read

Names in the registry

  • “Biological”, 2 entries
  • “AAV2-GDNF gene therapy”, 1 entry
  • “Biological/Vaccine: BNT162b2 10mcg”, 1 entry
  • “Biological/Vaccine: BNT162b2 3mcg”, 1 entry
  • “Biological/Vaccine: monovalent (hMPV) unlicensed comparator”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.